CorMedix Inc’s filing revealed that its EVP, Chief Commercial Officer Mistry Erin acquired Company’s shares for reported $14985.0 on Oct 31 ’24. In the deal valued at $9.99 per share,1,500 shares were bought. As a result of this transaction, Mistry Erin now holds 52,011 shares worth roughly $0.66 million.
Then, Hurlburt Elizabeth sold 140,027 shares, generating $1,565,670 in total proceeds. Upon selling the shares at $11.18, the EVP now owns 45,397 shares.
Before that, Hurlburt Elizabeth bought 140,027 shares. CorMedix Inc shares valued at $1,556,416 were divested by the Officer at a price of $11.12 per share.
Leerink Partners initiated its CorMedix Inc [CRMD] rating to an Outperform in a research note published on March 07, 2025; the price target was $18. A number of analysts have revised their coverage, including D. Boral Capital’s analysts, who began to cover the stock in mid January with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering CRMD with “Buy” recommendation on August 26, 2024. RBC Capital Mkts started covering the stock on August 10, 2023. It rated CRMD as “an Outperform”.
Price Performance Review of CRMD
On Monday, CorMedix Inc [NASDAQ:CRMD] saw its stock jump 3.83% to $12.75. Over the last five days, the stock has gained 7.50%. CorMedix Inc shares have risen nearly 57.41% since the year began. Nevertheless, the stocks have risen 142.86% over the past one year.
How much short interest is there in CorMedix Inc?
A steep rise in short interest was recorded in CorMedix Inc stocks on 2025-04-30, growing by 0.12 million shares to a total of 8.04 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 7.92 million shares. There was a rise of 1.48%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 17, 2021 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $31 price target.
